T1	Participants 1083 1140	The study was conducted from June 3, 2011, to May 2, 2013
T2	Participants 680 958	Eligibility included adults with an estimated life expectancy of between 1 month and 1 year, statin therapy for 3 months or more for primary or secondary prevention of cardiovascular disease, recent deterioration in functional status, and no recent active cardiovascular disease
